1-20 of 7170 Search Results for

c-jun

Follow your search
Access your saved searches in your account

Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles
Cancer Res (2021) 81 (13_Supplement): 986.
Published: 01 July 2021
... by E11.1. Concomitant drug treatment of E11.1 and histone deacetylase (HDAC) inhibitor (suberoylanilide hydroxamic acid or romidepsin) was tested for synergistic action in lytic induction and cell death. E11.1 elicited a rapid kinetics of lytic induction through the activation of c-Jun N-terminal kinase...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 6024.
Published: 15 August 2020
... activation of the proto-oncogene c-Jun in αvβ3+ stem-like cells. Inhibition of JNK/c-Jun signaling further identified the receptor tyrosine kinase AXL as a critical downstream target gene necessary for tumorsphere formation. Our findings reveal a c-Jun/AXL signaling pathway required for stemness properties...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 604.
Published: 15 August 2020
... treatment accelerated an accumulation of mitotic catastrophe with mitotic arrest, and led to apoptotic cell death. Mechanistically, combination TAS-119 and adavosertib in HNSCC cells drastically augmented DNA damage and phosphorylation of c-Jun (Ser 63) as demonstrated by kinase array and western blotting...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 498.
Published: 15 August 2020
... signaling pathway by repressing WNT5B. Furthermore, WNT5B recombinant protein significantly increased (P<0.05) the OCSC population, and Reverse Phase Protein Array (RPPA) analysis demonstrated activation of non-canonical WNT signaling via C-JUN as a possible downstream target of WNT5B. Collectively, our...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 5067.
Published: 15 August 2020
... and metastasis of triple-negative breast cancer (TNBC) by c-Jun N-Terminal Kinase (JNK) inhibitor via reversing immunosuppressive tumor microenvironment (TME) [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA...
Journal Articles
Cancer Res (2020) 80 (16_Supplement): 4223.
Published: 15 August 2020
..., Ruibao Ren. Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-Jun N-terminal kinase inhibition [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 1783.
Published: 15 June 2022
... by monitoring cleaved-PARP and flow cytometry using Annexin/7AAD staining. MDR1 expression was studied using qRT-PCR and western-blot. JNK/c-Jun pathway was studied by pJNK and cJun expressions, cJun transcriptional activity, ChIP assay and pharmacological inhibition. Results: LBD-ER cells exhibited higher...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 2754.
Published: 15 June 2022
... (scFv) derived from an R12 rabbit monoclonal antibody that recognizes and binds with high specificity to human ROR1. Gen-R is ex vivo genetic reprogramming technology that engineers CAR T cells to overexpress c-Jun. Dysregulation of activator protein 1 (AP-1) has been implicated in CAR T-cell...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 110.
Published: 15 June 2022
... expression by platycodin D treatment was through activation of the c-Jun N-terminal kinase (JNK) and AP-1 dependent transcription since JNK inhibitor or over-expression of dominant negative c-Jun abolished the elevated PUMA expression. Moreover, knockdown of JNK1, but not JNK2, significantly decreased...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5723.
Published: 15 June 2022
...Wei-Hsiung Yang; Kasey Price; Leticia Cardoso; William Yang; Chiung-Min Wang; Richard Yang USAAP-1 protein mainly consists of proteins belonging to c-Jun, c-Fos, activating transcription factor (ATF), and Jun dimerization protein (JDP) family. In addition to AP-1 site, JDP2 also binds to cAMP...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 411.
Published: 15 June 2022
... and transcription factors known to drive oncogenic and survival programs in tumors like c-Myc, c-Jun, FOXOs are induced upon continuous long-term PI3K inhibition (2 weeks and longer). These changes increase as a function of duration of inhibition and become less reversible with time in drug. Unbiased clustering...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5843.
Published: 15 June 2022
..., and decreased expression of several WNT-target genes (e.g. LGR5, CD44, c-Jun, c-Myc, Cyclin D1), particularly genes that have reported roles in cell cycle regulation. These findings were consistent with our independent bioinformatics analyses of NCI TCGA RNA-seq data on CRC patients. Overall, our study suggests...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): LB568.
Published: 15 June 2022
... been reported to be overexpressed in breast, lung and pancreatic cancers. PP4 plays an important role in the regulation of centrosome maturation, DNA repair, NF-κB, and c-jun-NH2-kinase (JNK) signaling pathways. However, the expression and functions of PP4 in pancreatitis have not been...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3004.
Published: 15 June 2022
... organelles and macromolecules in maintaining proteome homeostasis, and it is suppressed by the mammalian target of rapamycin complex 1 (mTORC1), a master regulator of translation and autophagy. mTOR activity is known to be activated by AMP-activated protein kinase (AMPK) and negatively regulated by c-Jun N...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3082.
Published: 15 June 2022
... mimetic of tobacco smoke. Through RNA sequencing analysis of these organoids, we have identified two distinct gene expression states that accompany either early or late dysplasia. By performing gene set enrichment analysis of these two distinct gene signatures, we have identified c-Jun N-terminal Kinase...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 6371.
Published: 15 June 2022
...Tae-Rim Lee; Jin Mo Ahn; Joo Hyuk Sohn; Sook Ryun Park; Min Hwan Kim; Gun Min Kim; Ki-Byung Song; Eunsung Jun; Dongryul Oh; Jeong-Won Lee; Joseph J Noh; Young Sik Park; Sun-Young Kong; Sang Myung Woo; Bo Hyun Kim; Eui Kyu Chie; Hyun-Cheol Kang; Youn Jin Choi; Ki-Won Song; Jeong-Sik Byeon; Junnam...
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 5726.
Published: 15 June 2022
...Yukyung Jun; Yun-Suhk Suh; SungHee Park; Jieun Lee; Jong-Il Kim; Sanghyuk Lee; Wan-Ping Lee; Olga Anczuków; Han-Kwang Yang; Charles Lee Alternatively spliced RNA isoforms are a hallmark of tumors, but their nature, prevalence, and clinical implications in gastric cancer are unknown. We...
Images
Signaling pathways associated with METTL3 expression in bladder cancer.  A ...
Published: 03 May 2022
Figure 3. Signaling pathways associated with METTL3 expression in bladder cancer. A and B, Ranked lists ( A ) and bubble plot ( B ) show 11 pathways analyzed by GSEA of TCGA bladder cancer dataset. C, Enrichment plots show the MAPK pathway analyzed by GSEA of TCGA bladder cancer dataset (top) and GEO datasets (bottom). NES, normalized enrichment score. D and E, Quantitative measurement of phosphorylated c-Jun and JNK1 in human ( D )/mice ( E ) bladder tumor tissues (n = 35 for human samples; n = 12 for mice samples) and PT tissue (n = 35 for PT; n = 10 for normal tissues). Immunostaining was quantitatively measured using ImageJ analysis software. Data are presented as mean ± SD of independent samples with individual data points shown and P values were assessed by two-tailed Student t test in comparison with the noncancerous group ( D and E ). **, P < 0.01; ***, P < 0.001. p-JNK1, phosphorylated JNK1; phosphorylated c-Jun, p-c-Jun; NOM P value, nominal P value. Figure 3. Signaling pathways associated with METTL3 expression in bladder cancer. Ranked lists (A) and bubble plot (B) show 11 pathways analyzed by GSEA of TCGA bladder cancer dataset. C, Enrichment plots show the MAPK pathway analyzed by GSEA of TCGA bladder cancer dataset (top) and GEO datasets (bottom). NES, normalized enrichment score. Quantitative measurement of phosphorylated c-Jun and JNK1 in human (D)/mice (E) bladder tumor tissues (n = 35 for human samples, n = 12 for mice samples), and PT tissue (n = 35 for PT, n = 10 for normal tissues). Immunostaining was quantitatively measured using Image J analysis software. Data are presented as mean ± SD of independent samples with individual data points shown and P values were assessed by two-tailed Student t test in comparison with the noncancerous group (D, E). *, **, and *** indicate P < 0.05, 0.01, and 0.001 respectively. p-JNK1, phosphorylated JNK1; phosphorylated c-Jun, p-c-Jun. More
Journal Articles
Cancer Res (2022) 82 (9): 1789–1802.
Published: 03 May 2022
... (top) and GEO datasets (bottom). NES, normalized enrichment score. D and E, Quantitative measurement of phosphorylated c-Jun and JNK1 in human ( D )/mice ( E ) bladder tumor tissues (n = 35 for human samples; n = 12 for mice samples) and PT tissue (n = 35 for PT...
Includes: Supplementary data
Journal Articles
Cancer Res (2022) 82 (12_Supplement): 3581.
Published: 15 June 2022
...Katherine E. Masih; Rebecca Gardner; Hsien-Chao Chou; Abdalla Abdelmaksoud; Young K. Song; Luca Mariani; Vineela Gangalapudi; Berkley E. Gryder; Ashley Wilson; Serifat O. Adebola; Benjamin Z. Stanton; Chaoyu Wang; Xinyu Wen; Gregoire Altan-Bonnet; Michael C. Kelly; Jun S. Wei; Martha L. Bulyk...